Paxlovid and Lagevrio Benefit COVID Outpatients in Omicron Era September 19, 2023

[lankisterguy]

The American College of Physicians has issued an updated version of its living, rapid practice point guideline on the best treatment options for outpatients with confirmed COVID-19 in the era of the dominant Omicron variant of SARS-CoV-2.

-

The recommendations in version 2 ( the MedScape version is easier to read medscape.com/s/viewarticle/... ) :

Consider the oral antivirals nirmatrelvir-ritonavir (Paxlovid) or molnupiravir (Lagevrio) for symptomatic outpatients with confirmed mild to moderate COVID-19 who are within 5 days of the onset of symptoms and at high risk for progressing to severe disease and potential hospitalization or death.

-

The ACP version written in "high doctor" Med-Speak with graphics and charts: acpjournals.org/doi/10.7326...

Outpatient Treatment of Confirmed COVID-19: Living, Rapid Practice Points From the American College of Physicians (Version 2)

Although COVID-19 is no longer a global health emergency according to the World Health Organization and Centers for Disease Control and Prevention, it remains an ongoing health issue for which evidence continues to emerge addressing clinical dilemmas, such as the choice of treatment (1, 2). Management of most adults with COVID-19, especially those with mild to moderate disease, is increasingly occurring in the outpatient setting due to the availability of treatment options. This version (version 2) of the American College of Physicians (ACP) Population Health and Medical Science Committee’s (PHMSC) living, rapid practice points presents advice about the treatment of adults with confirmed COVID-19 in outpatient settings, regardless of SARS-CoV-2 vaccination status. Mutations of the SARS-CoV-2 virus are continuously emerging, and they affect how well treatments for COVID-19 work (3, 4). This version of the practice points evaluates evidence specific to the SARS-CoV-2 Omicron variant becoming the dominant variant of concern. Version 1 of these practice points was published on 29 November 2022 (5). Appendix Table 1 summarizes changes in the methods, and Appendix Table 2 summarizes changes in the practice point statements between version 1 and version 2. Table 1 (6–15) and Figures 1 and 2 (14, 16) summarize the current evidence.

-

Len

[Skyshark]

Over 1.4m on studies, 61.5% female, 38.5% male. Almost the opposite ratio of male/female incidence of CLL.

[JerrysGirl3]

When I had Covid shortly after starting Zanubrutinib, I felt the Paxlovid really boosted my immune system and when disease progression was over, my CLL numbers were almost normal for a very long time.